患者さんに合わせた糖尿病治療ができる　血糖管理と薬剤選択の大原則

出版社： 羊土社
著者：
発行日： 2022-11-10
分野： 臨床医学：内科  >  糖尿病
ISBN： 9784758123570
電子書籍版： 2022-11-10 （第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

5,280 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,280 円(税込)

購入する

商品紹介

患者の病態やライフスタイルに合った糖尿病薬の選択や調節，地域連携，在宅管理，患者指導のコツなど，血糖管理で困らないためにかかりつけ医が必ず知っておきたいことを集めました！

目次

  • 第1章　病態に合わせた処方の基本
    1　糖尿病処方薬の動向は？
    2　糖尿病予防に役立つ処方は？
    3　ガイドラインに基づいた2型糖尿病の処方は？
    4　肥満が気になる人の処方は？
    5　医療費が気になる人への処方は？
    6　新しい糖尿病薬の使い方は？ ～イメグリミンの特徴は？
    7　血糖コントロールが悪くなったとき，どうする？
    8　神経障害を訴える患者の処方は？
    9　網膜症を伴う人への処方は？
    10　腎機能が気になる患者の処方は？
    11　糖尿病足病変を抱える人への処方は？

    第2章　糖尿病薬による副作用
    1　低血糖が気になる患者への処方は？
    2　気になる糖尿病薬による皮膚疾患は？
    3　SGLT2阻害薬によるフルニエ壊疽とは？
    4　糖尿病薬の効果や副作用に配慮した療養指導は？

    第3章　特殊な病態の治療
    1　1型糖尿病への対応のコツは？
    2　若年2型糖尿病の処方は？
    3　妊娠糖尿病への処方は？
    4　高齢者への糖尿病薬の処方は？
    5　ステロイド糖尿病の処方は？
    6　膵性糖尿病の処方は？
    7　周術期の血糖管理は？ ～術前患者の血糖コントロールで大事なことは？
    8　経腸栄養時における血糖管理は？
    9　高度な肥満を伴う糖尿病の外科治療は？

    第4章　困ったときへの対応
    1　糖質制限を行っている人への処方は？
    2　運動嫌いな人への処方は？
    3　薬を飲みたくない人への対応は？
    4　薬を飲み忘れる人への対応は？
    5　災害に備えた処方の注意点は？
    6　注射を嫌がる人への対応は？
    7　注射の効きが悪いときの対応は？
    8　注射の手技が気になる人への対応は？

    第5章　地域連携
    1　糖尿病連携手帳の使い方は？
    2　医療機関と連携するコツは？
    3　薬局を活用するには？ ～糖尿病治療における医-薬-栄連携とは？

    第6章　先進医療の活用
    1　処方に活かすSMBGの活用方法は？
    2　薬物治療に活かすCGMの活用は？
    3　インスリンポンプについて聞かれたら
    4　遺伝子解析を用いた糖尿病薬選択の個別化

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 病態に合わせた処方の基本

P.20 掲載の参考文献
1) Yokoyama H, et al : The Prognosis of Patients With Type 2 Diabetes and Nonalbuminuric Diabetic Kidney Disease Is Not Always Poor : Implication of the Effects of Coexisting Macrovascular Complications (JDDM 54). Diabetes Care, 43 : 1102-1110, 2020 [PMID : 32144168]
 
2) Yokoyama H, et al : Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan : a long-term view of real-world treatment between 2002 and 2018 (JDDM 66). BMJ Open Diabetes Res Care, 10 : doi : 10.1136/bmjdrc-2021-002727, 2022 [PMID : 35504696]
PubMed
3) Yokoyama H, et al : Albuminuria, C-reactive protein, and socioeconomic factors are associated with periodontal status in subjects with type 2 diabetes. Diabetol Int, 10 : 250-259, 2019 [PMID : 31592401]
 
4) Yokoyama H, et al : Applications of physical performance measures to routine diabetes care for frailty prevention concept : fundamental data with grip strength, gait speed, timed chair stand speed, standing balance, and knee extension strength. BMJ Open Diabetes Res Care, 8 : doi : 10.1136/bmjdrc-2020-001562, 2020 [PMID : 32948539]
 
5) Maegawa H, et al : Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs : Results from a Japanese cohort study (JDDM53). J Diabetes Investig, 12 : 374-381, 2021 [PMID : 32643314]
 
P.27 掲載の参考文献
1) Hostalek U & Campbell I : Metformin for diabetes prevention : update of the evidence base. Curr Med Res Opin, 37 : 1705-1717, 2021 [PMID : 34281467]
 
2) Madsen KS, et al : Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev, 12 : CD008558, 2019 [PMID : 31794067]
 
3) Domecq JP, et al : Medications affecting the biochemical conversion to type 2 diabetes : A systematic review and meta-analysis. J Clin Endocrinol Metab : doi : 10.1210/jc.2019-01269, 2019 [PMID : 31365088]
 
4) Moelands SV, et al : Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev, 12 : CD005061, 2018 [PMID : 30592787]
PubMed
5) DeFronzo RA, et al : Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med, 364 : 1104-1115, 2011 [PMID : 21428766]
 
6) Kawamori R, et al : Voglibose for prevention of type 2 diabetes mellitus : a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet, 373 : 1607-1614, 2009 [PMID : 19395079]
 
7) Nazarzadeh M, et al : Blood pressure lowering and risk of new-onset type 2 diabetes : an individual participant data meta-analysis. Lancet, 398 : 1803-1810, 2021 [PMID : 34774144]
 
8) Crandall JP, et al : Statin use and risk of developing diabetes : results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care, 5 : e000438, 2017 [PMID : 29081977]
 
9) Crandall JP, et al : Statin use and risk of developing diabetes : results from the Diabetes Prevention Program. BMJ Open Diabetes Res Care, 5 : e000438, 2017 [PMID : 29081977]
 
10) 糖尿病・発症予測ツール : 大阪がん循環器病予防センター http://www.osaka-ganjun.jp/health/d-estimate/
 
11) 笹井浩行, 他 : 特定保健指導での活用を目指した糖尿病発症リスク予測シートの開発. 日本公衆衛生雑誌, 55 : 287-294, 2008
 
12) 糖尿病危険度予測シート 第二版 : 茨城県 https://www.pref.ibaraki.jp/hokenfukushi/chiiki/kenko/documents/4diabetes_risk_sheetman.pdf
 
13) Nanri A, et al : Development of Risk Score for Predicting 3-Year Incidence of Type 2 Diabetes : Japan Epidemiology Collaboration on Occupational Health Study. PLoS One, 10 : e0142779, 2015 [PMID : 26558900]
 
P.35 掲載の参考文献
1) 「糖尿病受診中断対策包括ガイド」作成ワーキンググループ : 糖尿病受診中断対策包括ガイド. 2014 https://human-data.or.jp/wp/wp-content/uploads/2018/07/dm_jushinchudan_guide43_e.pdf
 
2) 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), 南江堂, 2019
 
3) Yoshinari M, et al : Comparison of the contributions of impaired beta cell function and insulin resistance to the development of type 2 diabetes in a Japanese community : the Hisayama Study. Diabetologia, 64 : 1775-1784, 2021 [PMID : 33909115]
 
4) 日本糖尿病・生活習慣病ヒューマンデータ学会 : 糖尿病標準診療マニュアル 2022 (一般診療所・クリニック向け). 2022 https://human-data.or.jp/wp/wp-content/uploads/2022/03/DMmanual_18.pdf
 
5) Noto H, et al : Cluster-randomized trial to improve the quality of diabetes management : The study for the efficacy assessment of the standard diabetes manual (SEAS-DM). J Diabetes Investig, 7 : 539-543, 2016 [PMID : 27181755]
 
6) Hong J, et al : Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care, 36 : 1304-1311, 2013 [PMID : 23230096]
 
7) Tanabe M, et al : Reduced vascular events in type 2 diabetes by biguanide relative to sulfonylurea : study in a Japanese Hospital Database. BMC Endocr Disord, 15 : 49, 2015 [PMID : 26382923]
 
8) Komaru Y, et al : Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome : Influence of diabetes and its management with medication. J Diabetes Complications, 34 : 107511, 2020 [PMID : 31928892]
 
9) American Diabetes Association : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S1-S264, 2022
PubMed
10) 日本糖尿病学会コンセンサスステートメント策定に関する委員会「2型糖尿病の薬物療法のアルゴリズム」 : 糖尿病 65 (8) : 419-434, 2022 http://www.fa.kyorin.co.jp/jds/uploads/65_419.pdf
 
P.42 掲載の参考文献
1) 厚生労働省 : 令和元年 国民健康・栄養調査結果の概要. 2020 https://www.mhlw.go.jp/content/10900000/000687163.pdf
 
2) JDDM : 2020年度 基礎集計資料 http://jddm.jp/public-information/index-2020/
 
3) 前田法一, 下村伊一郎 : 肥満症とアディポサイトカイン. 日本内科学会雑誌, 100 : 911-916, 2011
 
4) 田村好史, 他 : 異所性脂肪とインスリン抵抗性. 外科と代謝・栄養, 55 : 128-132, 2021
Medical*Online
5) 「糖尿病治療ガイド 2022-2023」 (日本糖尿病学会/編著), pp31-35, 文光堂, 2022
 
6) 厚生労働省 : 健康日本21目標値一覧 https://www.mhlw.go.jp/www1/topics/kenko21_11/t2a.html
 
7) 厚生労働省 : 健康づくりのための身体活動基準 2013/健康づくりのための身体活動指針 (アクティブガイド) ～いつでもどこでもプラス・テン https://www.mhlw.go.jp/stf/houdou/2r9852000002xple.html
 
8) UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352 : 854-865, 1998 [PMID : 9742977]
 
9) Kodama N, et al : Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocrinol Metab, 98 : 4438-4445, 2013 [PMID : 24030946]
PubMed
10) Lewis JD, et al : Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. JAMA, 314 : 265-277, 2015 [PMID : 26197187]
 
11) Koshizaka M, et al : Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin : A prospective, multicentre, open-label, blinded-endpoint, randomized controlled study (PRIME-V study). Diabetes Obes Metab, 21 : 1990-1995, 2019 [PMID : 30993861]
 
12) 上野浩晶, 中里雅光 : GLP-1受容体作動薬の体重減少効果. 糖尿病, 60 : 570-572, 2017
 
P.49 掲載の参考文献
1) 中村二郎, 神谷英紀 : 日本人糖尿病患者の寿命と死因. 糖尿病, 11 : 6-12, 2019
 
2) Draznin B, et al : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S125-S143, 2022 [PMID : 34964831]
 
3) Aroda VR, et al : Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII) : a multicentre, open-label, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol, 7 : 596-605, 2019 [PMID : 31189519]
 
4) Bray GA, et al : Dietary fat and obesity : a review of animal, clinical and epidemiological studies. Physiol Behav, 83 : 549-555, 2004 [PMID : 15621059]
 
5) Fukushima M, et al : Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract, 66 Suppl 1 : S37-S43, 2004 [PMID : 15563978]
 
6) Oe Y, et al : Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes : A Preliminary Prospective Observation Study. J Diabetes Res, 2022 : 5603864, 2022 [PMID : 35097130]
 
7) 加来浩平, 他 : 2型糖尿病治療におけるメトホルミンの使用実態に関する観察研究 (MORE study). 49 : 325-331, 2006
 
8) 難波光義, 他 : 糖尿病治療に関連した重症低血糖の調査委員会報告. 糖尿病, 60 : 826-842, 2017
 
9) UK Prospective Diabetes Study (UKPDS) Group : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352 : 854-865, 1998 [PMID : 9742977]
 
P.55 掲載の参考文献
1) Vial G, et al : Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes, 64 : 2254-2264, 2015 [PMID : 25552598]
 
2) Vial G, et al : The mechanism by which imeglimin inhibits gluconeogenesis in rat liver cells. Endocrinol Diabetes Metab, 4 : e00211, 2021 [PMID : 33855213]
 
3) Hallakou-Bozec S, et al : Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action. PLoS One, 16 : e0241651, 2021 [PMID : 33606677]
 
4) Pacini G, et al : Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab, 17 : 541-545, 2015 [PMID : 25694060]
 
5) Dubourg J, et al : Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1) : A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial. Diabetes Care, 44 : 952-959, 2021 [PMID : 33574125]
 
6) 住友ファーマ株式会社資料 : 国内第3相長期試験 (単独療法) 承認時評価資料 https://sumitomo-pharma.jp/information/twymeeg/useful/clinical/clinical02.html
 
7) 住友ファーマ株式会社資料 : 国内第3相長期試験 (単独および併用療法) 承認時評価資料 https://sumitomo-pharma.jp/information/twymeeg/useful/clinical/clinical03.html
 
8) 住友ファーマ株式会社資料 : 国内第3相長期試験 (インスリン併用療法) 承認時評価資料 https://sumitomo-pharma.jp/information/twymeeg/useful/clinical/clinical04.html
 
9) Seino Y, et al : Cephalic phase insulin secretion is KATP channel independent. J Endocrinol, 218 : 25-33, 2013 [PMID : 23608222]
 
10) Li J, et al : Imeglimin Ameliorates β-Cell Apoptosis by Modulating the Endoplasmic Reticulum Homeostasis Pathway. Diabetes, 71 : 424-439, 2022 [PMID : 34588186]
 
P.61 掲載の参考文献
1) 「糖尿病治療ガイド 2022-2023」 (日本糖尿病学会/編著), 文光堂, 2022
 
2) 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), 南江堂, 2019
 
3) Draznin B, et al : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S125-S143, 2022 [PMID : 34964831]
 
4) 能登洋 : 第47回 米国糖尿病学会2022年版診療ガイドライン速報 : エビデンスの活用か濫用か. m3.com, 2022年1月21日 (金) 配信 https://www.m3.com/clinical/news/1004082
 
5) 日本糖尿病・生活習慣病ヒューマンデータ学会 : 糖尿病標準診療マニュアル 2022 (一般診療所・クリニック向け). 2022 https://human-data.or.jp/wp/wp-content/uploads/2022/03/DMmanual_18.pdf
 
6) Sharma A, et al : Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. Gastroenterology, 155 : 730-739.e3, 2018 [PMID : 29775599]
 
7) Takikawa T, et al : New-Onset or Exacerbation of Diabetes Mellitus Is a Clue to the Early Diagnosis of Pancreatic Cancer. Tohoku J Exp Med, 252 : 353-364, 2020 [PMID : 33342915]
 
8) 日本糖尿病学会コンセンサスステートメント策定に関する委員会「2 型糖尿病の薬物療法のアルゴリズム」 : 糖尿病 65 (8) : 419-434, 2022 http://www.fa.kyorin.co.jp/jds/uploads/65_419.pdf
 
P.69 掲載の参考文献
1) Pop-Busui R, et al : Diabetic Neuropathy : A Position Statement by the American Diabetes Association. Diabetes Care, 40 : 136-154, 2017 [PMID : 27999003]
 
2) 麻生好正 : 糖尿病神経障害の疫学. 日本臨牀, 74 : 217-222, 2016
Medical*Online
3) 麻生好正 : 糖尿病性自律神経障害. 「徹底解説! 糖尿病合併症 管理・フォローアップ」 (麻生好正/編), pp70-76, 文光堂, 2021
 
4) 麻生好正 : 糖尿病性自律神経障害の治療-病態も含めて. 「ヴィジュアル糖尿病臨床のすべて 糖尿病性神経障害」 (中村二郎/専門編集, 荒木栄一/編集主幹), pp168-178, 中山書店, 2013
 
5) 糖尿病性神経障害を考える会 : 糖尿病性多発神経障害 (distal symmetric polyneuropathy) の簡易診断基準 (小改定版). 末梢神経, 12 : 225-227, 2001
 
6) Hotta N, et al : Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy : the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care, 29 : 1538-1544, 2006 [PMID : 16801576]
 
7) Yasuda H, et al : Superiority of duloxetine to placebo in improving diabetic neuropathic pain : Results of a randomized controlled trial in Japan. J Diabetes Investig, 2 : 132-139, 2011 [PMID : 24843472]
 
8) Baba M, et al : Long-term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain. J Diabetes Investig, 11 : 693-698, 2020 [PMID : 31722446]
 
9) Tesfaye S, et al : Painful diabetic peripheral neuropathy : consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev, 27 : 629-638, 2011 [PMID : 21695762]
 
P.75 掲載の参考文献
1) Ohkubo Y, et al : Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study. Diabetes Res Clin Pract, 28 : 103-117, 1995 [PMID : 7587918]
 
2) Kawasaki R, et al : Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes : 8 year follow-up study of the Japan Diabetes Complications Study (JDCS). Diabetologia, 54 : 2288-2294, 2011 [PMID : 21630126]
 
3) Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group : Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA, 287 : 2563-2569, 2002 [PMID : 12020338]
 
4) Lachin JM, et al : Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med, 342 : 381-389, 2000 [PMID : 10666428]
 
5) UK Prospective Diabetes Study (UKPDS) Group : Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352 : 837-853, 1998 [PMID : 9742976]
 
6) Chaturvedi N, et al : Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet, 351 : 28-31, 1998 [PMID : 9433426]
 
7) Sjolie AK, et al : Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2) : a randomised placebo-controlled trial. Lancet, 372 : 1385-1393, 2008 [PMID : 18823658]
 
8) Keech AC, et al : Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study) : a randomised controlled trial. Lancet, 370 : 1687-1697, 2007 [PMID : 17988728]
 
9) Chew EY, et al : Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med, 363 : 233-244, 2010 [PMID : 20587587]
 
10) Elman MJ, et al : Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology, 117 : 1064-1077.e35, 2010 [PMID : 20427088]
 
11) 「高血圧治療ガイドライン 2019」 (日本高血圧学会高血圧治療ガイドライン作成委員会/編), ライフサイエンス出版, 2019 https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf
 
12) Suto C, et al : Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol, 124 : 38-45, 2006 [PMID : 16401783]
 
P.82 掲載の参考文献
1) 「エビデンスに基づく CKD診療ガイドライン 2018」 (日本腎臓学会/編), 東京医学社, 2018
 
2) 「エビデンスに基づく CKD診療ガイドライン 2013」 (日本腎臓学会/編), 東京医学社, 2013
 
3) 腎臓ネットPro : 腎臓病診療の最先端, Vol. 28 (稲葉雅章/監), 第3章 : CKDにおける糖尿病治療のエビデンス https://jinzounet.pro/特集28第3章/
 
4) Kidney Disease : Improving Global Outcomes (KDIGO) Diabetes Work Group : KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int, 98 : S1-S115, 2020 [PMID : 32998798]
 
5) Draznin B, et al : 16. Diabetes Care in the Hospital : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S244-S253, 2022 [PMID : 34964884]
 
6) 厚生労働省 : 健康日本21 (第二次) https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kenkounippon21.html
 
7) Perkovic V, et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 380 : 2295-2306, 2019 [PMID : 30990260]
 
P.86 掲載の参考文献
1) 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), 南江堂, 2019
 
2) Resnick HE, et al : Relation of lower-extremity amputation to all-cause and cardiovascular disease mortality in American Indians : the Strong Heart Study. Diabetes Care, 27 : 1286-1293, 2004 [PMID : 15161777]
 
3) Waaijman R, et al : Risk factors for plantar foot ulcer recurrence in neuropathic diabetic patients. Diabetes Care, 37 : 1697-1705, 2014 [PMID : 24705610]
 
4) Calle-Pascual AL, et al : Reduction in foot ulcer incidence : relation to compliance with a prophylactic foot care program. Diabetes Care, 24 : 405-407, 2001 [PMID : 11213900]
 
5) 「診療に役立つ糖尿病神経障害の新知識」 (豊田隆謙/監, 八木橋操六/編), pp19-20, 東京医学社, 2008
 
6) Xie X, et al : The clinical effectiveness of negative pressure wound therapy : a systematic review. J Wound Care, 19 : 490-495, 2010 [PMID : 21135797]
 
7) Rathsman B, et al : Intensified insulin treatment is associated with improvement in skin microcirculation and ischaemic foot ulcer in patients with type 1 diabetes mellitus : a long-term follow-up study. Diabetologia, 57 : 1703-1710, 2014 [PMID : 24802206]
 
8) Neal B, et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med, 377 : 644-657, 2017 [PMID : 28605608]
 
9) 「糖尿病治療ガイド 2022-2023」 (日本糖尿病学会/編著), 文光堂, 2022
 

第2章 糖尿病薬による副作用

P.94 掲載の参考文献
1) Bloomfield HE, et al : Predictors and Consequences of Severe Hypoglycemia in Adults with Diabetes-A Systematic Review of the Evidence [Internet], VA Evidence-based Synthesis Program Reports, 2012 [PMID : 23256228]
 
2) Bahrami J, et al : Impaired awareness of hypoglycaemia in women with type 1 diabetes in pregnancy : Hypoglycaemia fear, glycaemic and pregnancy outcomes. Diabet Med, 39 : e14789, 2022 [PMID : 35030277]
 
3) Woodward A, et al : Nocturnal hypoglycaemia in type 1 diabetes--frequency and predictive factors. QJM, 102 : 603-607, 2009 [PMID : 19574471]
 
4) Rodbard D : Glucose Time In Range, Time Above Range, and Time Below Range Depend on Mean or Median Glucose or HbA1c, Glucose Coefficient of Variation, and Shape of the Glucose Distribution. Diabetes Technol Ther, 22 : 492-500, 2020 [PMID : 31886733]
 
5) Draznin B, et al : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S125-S143, 2022 [PMID : 34964831]
 
6) Tourkmani AM, et al : Hypoglycemia in Type 2 Diabetes Mellitus patients : A review article. Diabetes Metab Syndr, 12 : 791-794, 2018 [PMID : 29678605]
 
7) Perea V, et al : Impaired awareness of hypoglycaemia : A new risk factor for adverse pregnancy outcomes in type 1 diabetes. Diabetes Metab Res Rev, 35 : e3176, 2019 [PMID : 31066196]
 
8) Goto A, et al : Association Between Severe Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With Type 2 Diabetes. J Am Heart Assoc, 5 : e002875, 2016 [PMID : 26961698]
 
P.99 掲載の参考文献
1) Bene J, et al : Bullous pemphigoid and dipeptidyl peptidase IV inhibitors : a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol, 175 : 296-301, 2016 [PMID : 27031194]
 
2) Arai M, et al : Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors : A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care, 41 : e130-e132, 2018 [PMID : 30002201]
 
3) Ujiie H, et al : HLA-DQB1*03 : 01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors. J Invest Dermatol, 138 : 1201-1204, 2018 [PMID : 29203362]
 
4) Horikawa H, et al : Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors. Br J Dermatol, 178 : 1462-1463, 2018 [PMID : 29478242]
 
5) 木村徹子, 他 : DPP-4 (dipeptidyl peptidase-4) 阻害薬内服後に発症した水疱性類天疱瘡患者の臨床病型の検討. 日本皮膚科学会雑誌, 128 : 2645-2651, 2018
 
6) Kawaguchi Y, et al : Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid : A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. J Diabetes Investig, 10 : 392-398, 2019 [PMID : 29920976]
 
7) Schmidt E & Zillikens D : Pemphigoid diseases. Lancet, 381 : 320-332, 2013 [PMID : 23237497]
 
8) Douros A, et al : Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes. Diabetes Care, 42 : 1496-1503, 2019 [PMID : 31182489]
 
9) Izumi K, et al : Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid. J Invest Dermatol, 136 : 2201-2210, 2016 [PMID : 27424319]
 
10) Plaquevent M, et al : Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. J Invest Dermatol, 139 : 835-841, 2019 [PMID : 30543900]
 
P.104 掲載の参考文献
1) Bakris GL : Major Advancements in Slowing Diabetic Kidney Disease Progression : Focus on SGLT2 Inhibitors. Am J Kidney Dis, 74 : 573-575, 2019 [PMID : 31262591]
 
2) Yagi N, et al : Current status of oral antidiabetic drug prescribing patterns based on the body mass index for Japanese type 2 diabetes mellitus patients and yearly changes in diabetologists' prescribing patterns from 2002 to 2019 (JDDM61). J Diabetes Investig, 13 : 65-73, 2022 [PMID : 34191401]
 
3) 石川耕資, 他 : 壊死性筋膜炎と重症蜂窩織炎の鑑別診断におけるLRINEC scoreの有用性の検討. 創傷, 5 : 22-26, 2014
 
4) Wong CH, et al : The LRINEC (Laboratory Risk Indicator for Necrotizing Fasciitis) score : a tool for distinguishing necrotizing fasciitis from other soft tissue infections. Crit Care Med, 32 : 1535-1541, 2004 [PMID : 15241098]
 
5) Eke N : Fournier's gangrene : a review of 1726 cases. Br J Surg, 87 : 718-728, 2000 [PMID : 10848848]
 
6) Tran BA, et al : Sodium-Glucose Cotransporter 2 Inhibitor Use Associated With Fournier's Gangrene : A Review of Case Reports and Spontaneous Post-Marketing Cases. Clin Diabetes, 40 : 78-86, 2022 [PMID : 35221476]
 
7) Zelniker TA, et al : SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes : a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 393 : 31-39, 2019 [PMID : 30424892]
 
8) 川田剛裕, 他 : 日本人2型糖尿病患者に対するイプラグリフロジン投与52週間の有効性と安全性に関する前向き介入研究. 糖尿病, 62 : 649-658, 2019
 
9) U.S. FOOD & DRUG : FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes https://www.fda.gov/Drugs/DrugSafety/ucm617360.htm
 
10) 今石奈緒, 他 : SGLT2阻害薬 (ダパグリフロジン) を服用中にフルニエ壊疽を発症した高齢2型糖尿病の1例. 糖尿病, 62 : 389-397, 2019
 
P.111 掲載の参考文献
1) Bonnet F & Scheen A : Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab, 19 : 473-481, 2017 [PMID : 27987248]
 
2) Infante M, et al : Long-term metformin therapy and vitamin B12 deficiency : An association to bear in mind. World J Diabetes, 12 : 916-931, 2021 [PMID : 34326945]
 
3) Hawley JA, et al : Mimicking exercise : what matters most and where to next? J Physiol, 599 : 791-802, 2021 [PMID : 31749163]
 
4) Zanchi A, et al : Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab, 89 : 1140-1145, 2004 [PMID : 15001599]
 
5) Nakamura A, et al : Relationship between urinary sodium excretion and pioglitazone-induced edema. J Diabetes Investig, 1 : 208-211, 2010 [PMID : 24843434]
 
6) Majima T, et al : Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J, 53 : 325-330, 2006 [PMID : 16710073]
 
7) Ida S, et al : Effects of pioglitazone treatment on blood leptin levels in patients with type 2 diabetes. J Diabetes Investig, 9 : 917-924, 2018 [PMID : 29194996]
 
8) Iwasaki M, et al : Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes : Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig, 3 : 464-467, 2012 [PMID : 24843607]
 
9) Sakane N, et al : The study of metabolic improvement by nutritional intervention controlling endogenous GIP (Mini Egg study) : a randomized, cross-over study. Nutr J, 18 : 52, 2019 [PMID : 31477157]
 

第3章 特殊な病態の治療

P.119 掲載の参考文献
1) 一般社団法人糖尿病データマネジメント研究会報告 : 2020年度 基礎集計資料-3. 各年度の平均HbA1c推移-http://jddm.jp/public-information/index-2020/
 
2) Ahlqvist E, et al : Novel subgroups of adult-onset diabetes and their association with outcomes : a datadriven cluster analysis of six variables. Lancet Diabetes Endocrinol, 6 : 361-369, 2018 [PMID : 29503172]
 
3) Tanabe H, et al : Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups : A Japanese Retrospective Cohort Study. J Clin Med, 9 : doi : 10.3390/jcm9072083, 2020 [PMID : 32630741]
 
4) Yokoyama H, et al : Declining trends of diabetic nephropathy, retinopathy and neuropathy with improving diabetes care indicators in Japanese patients with type 2 and type 1 diabetes (JDDM 46). BMJ Open Diabetes Res Care, 6 : e000521, 2018 [PMID : 29892340]
 
P.125 掲載の参考文献
1) Urakami T, et al : Urine glucose screening program at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan. Pediatr Res, 61 : 141-145, 2007 [PMID : 17237712]
 
2) Bjornstad P, et al : Long-Term Complications in Youth-Onset Type 2 Diabetes. N Engl J Med, 385 : 416-426, 2021 [PMID : 34320286]
 
3) Hamman RF, et al : The SEARCH for Diabetes in Youth study : rationale, findings, and future directions. Diabetes Care, 37 : 3336-3344, 2014 [PMID : 25414389]
 
4) 堀川幸男 : Maturity-onset diabetes of the young. 糖尿病, 62 : 461-463, 2019
 
5) 日本糖尿病学会 : 単一遺伝子異常による糖尿病の成因, 診断, 治療に関する調査研究委員会からのお願い. 2020 http://www.jds.or.jp/modules/study/index.php?content_id=33
 
6) Laffel L, et al : Metformin monotherapy in youth with recent onset type 2 diabetes : experience from the prerandomization run-in phase of the TODAY study. Pediatr Diabetes, 13 : 369-375, 2012 [PMID : 22369102]
 
7) Jones KL, et al : Effect of metformin in pediatric patients with type 2 diabetes : a randomized controlled trial. Diabetes Care, 25 : 89-94, 2002 [PMID : 11772907]
 
8) Zeitler P, et al : ISPAD Clinical Practice Consensus Guidelines 2018 : Type 2 diabetes mellitus in youth. Pediatr Diabetes, 19 Suppl 27 : 28-46, 2018 [PMID : 29999228]
 
9) 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), 南江堂, 2019
 
10) American Diabetes Association : Introduction : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S1-S264, 2022 https://diabetesjournals.org/care/issue/45/Supplement_1
 
P.132 掲載の参考文献
1) Metzger BE, et al : Hyperglycemia and adverse pregnancy outcomes. N Engl J Med, 358 : 1991-2002, 2008 [PMID : 18463375]
 
2) 牧尉太, 他 : わが国における妊娠糖尿病の疫学-JAGS trialを用い新基準後におけるGDMの臨床背景を紐解く-. Diabetes Frontier, 27 : 578-584, 2016
Medical*Online
3) 「『妊娠と糖尿病』母児管理のエッセンス」 (難波光義, 杉山隆/編著), 金芳堂, 2013
 
4) Metzger BE, et al : International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care, 33 : 676-682, 2010 [PMID : 20190296]
 
5) 平松祐司, 他 : 日本糖尿病・妊娠学会と日本糖尿病学会との合同委員会妊娠中の糖代謝異常と診断基準の統一化について. 日本産科婦人科学会雑誌, 67 : 1656-1658, 2015
 
6) 安日一郎 : 妊娠と糖尿病 : 糖尿病合併妊娠のリスクと治療の留意点. 糖尿病プラクティス, 38 : 541-546, 2021
Medical*Online
7) 和栗雅子 : 妊娠糖尿病・糖尿病合併妊娠の母体予後. 産科と婦人科, 87 : 535-541, 2020
Medical*Online
8) Phelps RL, et al : Carbohydrate metabolism in pregnancy. XVII. Diurnal profiles of plasma glucose, insulin, free fatty acids, triglycerides, cholesterol, and individual amino acids in late normal pregnancy. Am J Obstet Gynecol, 140 : 730-736, 1981 [PMID : 7020420]
 
9) Metzger BE, et al : "Accelerated starvation" and the skipped breakfast in late normal pregnancy. Lancet, 1 : 588-592, 1982 [PMID : 6121184]
 
10) 「妊婦の糖代謝異常 診療・管理マニュアル 第3版」 (日本糖尿病・妊娠学会/編), メジカルビュー社, 2021
 
11) 日本産科婦人科学会 : 妊娠中の体重増加指導の目安について. 日本産婦人科学会雑誌, 73 : 642, 2021
 
12) 「産婦人科診療ガイドライン-産科編 2020」 (日本産科婦人科学会, 日本産婦人科医会/編), 2020 https://www.jsog.or.jp/activity/pdf/gl_sanka_2020.pdf
 
13) Catalano PM, et al : The hyperglycemia and adverse pregnancy outcome study : associations of GDM and obesity with pregnancy outcomes. Diabetes Care, 35 : 780-786, 2012 [PMID : 22357187]
 
14) 安日一郎 : 妊娠糖尿病および肥満2型糖尿病妊婦の食事療法. 糖尿病, 56 : 623-625, 2013
 
15) Jovanovic-Peterson L & Peterson CM : Dietary manipulation as a primary treatment strategy for pregnancies complicated by diabetes. J Am Coll Nutr, 9 : 320-325, 1990 [PMID : 2212389]
 
16) Rizzo T, et al : Correlations between antepartum maternal metabolism and intelligence of offspring. N Engl J Med, 325 : 911-916, 1991 [PMID : 1881416]
 
17) 妊婦の糖代謝異常. 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), pp283-304, 南江堂, 2019
 
18) Draznin B, et al : 15. Management of Diabetes in Pregnancy : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S232-S243, 2022 [PMID : 34964864]
 
19) Yamamoto JM, et al : Gestational Diabetes Mellitus and Diet : A Systematic Review and Meta-analysis of Randomized Controlled Trials Examining the Impact of Modified Dietary Interventions on Maternal Glucose Control and Neonatal Birth Weight. Diabetes Care, 41 : 1346-1361, 2018 [PMID : 29934478]
 
20) Han S, et al : Different types of dietary advice for women with gestational diabetes mellitus. Cochrane Database Syst Rev, 2 : CD009275, 2017 [PMID : 28236296]
 
21) 守屋達美, 他 : 食事・運動療法. 月刊 糖尿病, 5 : 47-54, 2013
 
22) Mathiesen ER, et al : Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy : a randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care, 30 : 771-776, 2007 [PMID : 17392539]
 
23) Mathiesen ER, et al : Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes. Diabetes Care, 35 : 2012-2017, 2012 [PMID : 22851598]
 
24) Gonzalez Blanco C, et al : Glycemic control and pregnancy outcomes in women with type 1 diabetes mellitus using lispro versus regular insulin : a systematic review and meta-analysis. Diabetes Technol Ther, 13 : 907-911, 2011 [PMID : 21714679]
 
25) Pollex E, et al : Safety of insulin glargine use in pregnancy : a systematic review and meta-analysis. Ann Pharmacother, 45 : 9-16, 2011 [PMID : 21205954]
 
26) Feig DS, et al : Metformin in women with type 2 diabetes in pregnancy (MiTy) : a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol, 8 : 834-844, 2020 [PMID : 32946820]
 
27) Morley LC, et al : Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev, 11 : CD003053, 2017 [PMID : 29183107]
 
28) Camelo Castillo W, et al : Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol, 123 : 1177-1184, 2014 [PMID : 24807336]
 
29) 厚生労働省 : 診療報酬の算定方法の一部改正に伴う実施上の留意事項について. 2016 https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000114848.pdf
 
30) American Diabetes Association : 14. Management of Diabetes in Pregnancy : Standards of Medical Care in Diabetes-2020. Diabetes Care, 43 : S183-S192, 2020 [PMID : 31862757]
 
31) National Institute for Health and Care Excellence (NICE) guideline https://www.nice.org.uk/
 
32) Yuji Hiramatsu, et al : Determination of reference intervals of glycated albumin and hemoglobin A1c in healthy pregnant Japanese women and analysis of their time courses and influencing factors during pregnancy. Endocr J, 59 : 145-151, 2012 [PMID : 22166921]
 
33) 清水一紀 : 糖尿病合併妊婦および妊娠糖尿病におけるグリコアルブミンと母児合併症に関する調査. 糖尿病と妊娠, 10 : 27-31, 2010
 
34) Bellamy L, et al : Type 2 diabetes mellitus after gestational diabetes : a systematic review and meta-analysis. Lancet, 373 : 1773-1779, 2009 [PMID : 19465232]
 
35) Lowe WL Jr, et al : Hyperglycemia and Adverse Pregnancy Outcome Follow-up Study (HAPO FUS) : Maternal Gestational Diabetes Mellitus and Childhood Glucose Metabolism. Diabetes Care, 42 : 372-380, 2019 [PMID : 30655380]
 
36) 内閣府 : 令和2年版少子化社会対策白書 第1部 少子化対策の現状 https://www8.cao.go.jp/shoushi/shoushika/whitepaper/measures/w-2020/r02webhonpen/html/b1_s1-1-3.html
 
P.140 掲載の参考文献
1) 厚生労働省 : 令和元年 国民健康・栄養調査報告. p161 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/r1-houkoku_00002.html
 
2) Araki A & Ito H : Diabetes mellitus and geriatric syndromes. Geriatr Gerontol Int, 9 : 105-114, 2009 [PMID : 19740352]
 
3) 「高齢者糖尿病診療ガイドライン 2017」 (日本老年医学会・日本糖尿病学会/編著), pp45-48, 南江堂, 2017
 
4) Mattishent K & Loke YK : Meta-Analysis : Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents. Front Endocrinol (Lausanne), 12 : 571568, 2021 [PMID : 33763024]
 
5) Wang CP, et al : Differential effects of metformin on age related comorbidities in older men with type 2 diabetes. J Diabetes Complications, 31 : 679-686, 2017 [PMID : 28190681]
 
6) Campbell JM, et al : Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control : A systematic review and meta-analysis. Ageing Res Rev, 40 : 31-44, 2017 [PMID : 28802803]
 
7) Karagiannis T, et al : GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes : A systematic review and meta-analysis. Diabetes Res Clin Pract, 174 : 108737, 2021 [PMID : 33705820]
 
8) 日本老年医学会 : DASC-8 (認知・生活機能質問票) を用いた高齢者の血糖コントロール目標設定のためのカテゴリー分類のしかた https://www.jpn-geriat-soc.or.jp/tool/dasc8.html
 
9) Lazarus B, et al : Association of Metformin Use With Risk of Lactic Acidosis Across the Range of Kidney Function : A Community-Based Cohort Study. JAMA Intern Med, 178 : 903-910, 2018 [PMID : 29868840]
 
10) Silbert R, et al : Hypoglycemia Among Patients with Type 2 Diabetes : Epidemiology, Risk Factors, and Prevention Strategies. Curr Diab Rep, 18 : 53, 2018 [PMID : 29931579]
 
11) Toyoshima K, et al : Use of Dementia Assessment Sheet for Community-based Integrated Care System 8-items (DASC-8) for the screening of frailty and components of comprehensive geriatric assessment. Geriatr Gerontol Int, 20 : 1157-1163, 2020 [PMID : 33067921]
 
P.146 掲載の参考文献
1) Gulliford MC, et al : Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care, 29 : 2728-2729, 2006 [PMID : 17130214]
 
2) Rizza RA, et al : Cortisol-induced insulin resistance in man : impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab, 54 : 131-138, 1982 [PMID : 7033265]
 
3) Pagano G, et al : An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest, 72 : 1814-1820, 1983 [PMID : 6355186]
 
4) Liu XX, et al : Hyperglycemia induced by glucocorticoids in nondiabetic patients : a meta-analysis. Ann Nutr Metab, 65 : 324-332, 2014 [PMID : 25402408]
 
5) 「糖尿病専門医研修ガイドブック 改訂第8版」 (日本糖尿病学会/編), p420, 診断と治療社, 2020
 
6) 「糖尿病治療ガイド 2022-2023」 (日本糖尿病学会/編著), p71, 文光堂, 2022
 
7) Roberts A, et al : Management of hyperglycaemia and steroid (glucocorticoid) therapy : a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabet Med, 35 : 1011-1017, 2018 [PMID : 30152586]
 
8) Li JX, et al : Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol, 18 : 1-18, 2022 [PMID : 35585199]
 
9) Bonaventura A, et al : Steroid-induced hyperglycemia : An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract, 139 : 203-220, 2018 [PMID : 29530386]
PubMed
10) Perez A, et al : Glucocorticoid-induced hyperglycemia. J Diabetes, 6 : 9-20, 2014 [PMID : 24103089]
 
11) Radhakutty A, et al : MANAGEMENT OF ENDOCRINE DISEASE : Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia Eur J Endocrinol, 179 : R207-R218, 2018 [PMID : 30299889]
 
12) Tamez-Perez HE, et al : Steroid hyperglycemia : Prevalence, early detection and therapeutic recommendations : A narrative review. World J Diabetes, 6 : 1073-1081, 2015 [PMID : 26240704]
 
13) Umpierrez GE, et al : Management of hyperglycemia in hospitalized patients in non-critical care setting : an endocrine society clinical practice guideline. J Clin Endocrinol Metab, 97 : 16-38, 2012 [PMID : 22223765]
 
14) Draznin B, et al : 16. Diabetes Care in the Hospital : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S244-S253, 2022 [PMID : 34964884]
 
15) Handelsman Y, et al : American Association of Clinical Endocrinologists and American College of Endocrinology-Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan-2015-Executive Summary. Endocr Pract, 21 : 413-437, 2015 [PMID : 27408942]
 
16) Pichardo-Lowden AR, et al : Management of hyperglycemia in the non-intensive care patient : featuring subcutaneous insulin protocols. Endocr Pract, 17 : 249-260, 2011 [PMID : 21041168]
 
17) Kwon S, et al : Glucocorticoid-induced hyperglycemia. Am J Med Sci, 345 : 274-277, 2013 [PMID : 23531958]
 
18) 令和4年度診療報酬改定 : C150 血糖自己測定器加算-7 間歇スキャン式持続血糖測定器によるもの
 
19) Wallace MD, et al : Optimizing the Treatment of Steroid-Induced Hyperglycemia. Ann Pharmacother, 52 : 86-90, 2018 [PMID : 28836444]
 
20) Hwang JL, et al : Steroid-induced diabetes : a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev, 30 : 96-102, 2014 [PMID : 24123849]
 
P.153 掲載の参考文献
1) Ito T, et al : Epidemiological study of pancreatic diabetes in Japan in 2005 : a nationwide study. Pancreas, 39 : 829-835, 2010 [PMID : 20182396]
 
2) Koizumi M, et al : Pancreatic diabetes in Japan. Pancreas, 16 : 385-391, 1998 [PMID : 9548683]
 
3) 「慢性膵炎診療ガイドライン 2015 改訂第2版」 (日本消化器病学会/編), 南江堂, 2015
 
4) 「急性膵炎診療ガイドライン 2015 第4版」 (急性膵炎診療ガイドライン 2015 改定出版委員会/編), 金原出版, 2015
 
5) 日本膵臓学会・厚生労働省IgG4関連疾患の診断基準並びに治療指針を目指す研究班 : 自己免疫性膵炎診療ガイドライン 2020. 膵臓, 35 : 465-550, 2020
Medical*Online
6) Scavini M, et al : Diabetes after pancreatic surgery : novel issues. Curr Diab Rep, 15 : 16, 2015 [PMID : 25702096]
 
7) Scott ES, et al : Sensor-augmented CSII therapy with predictive low-glucose suspend following total pancreatectomy. Endocrinol Diabetes Metab Case Rep, 2017 : doi : 10.1530/EDM-17-0093, 2017 [PMID : 29118986]
 
8) Permert J, et al : Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg, 80 : 1047-1050, 1993 [PMID : 8402064]
 
9) Elliott IA, et al : Population-Level Incidence and Predictors of Surgically Induced Diabetes and Exocrine Insufficiency after Partial Pancreatic Resection. Perm J, 21 : 16-095, 2017 [PMID : 28406793]
 
10) かかりつけ医から糖尿病専門医・専門医療機関への紹介基準 (日本糖尿病学会/作成, 日本医師会/監修) http://www.jds.or.jp/modules/important/index.php?content_id=92
 
P.159 掲載の参考文献
1) Raju TA, et al : Perioperative blood glucose monitoring in the general surgical population. J Diabetes Sci Technol, 3 : 1282-1287, 2009 [PMID : 20144381]
 
2) Frisch A, et al : Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care, 33 : 1783-1788, 2010 [PMID : 20435798]
 
3) 周術期管理. 「糖尿病専門医研修ガイドブック 改訂第8版」 (日本糖尿病学会/編), pp411-414, 診断と治療社, 2020
 
4) Malmberg K : Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ, 314 : 1512-1515, 1997 [PMID : 9169397]
 
5) van den Berghe G, et al : Intensive insulin therapy in critically ill patients. N Engl J Med, 345 : 1359-1367, 2001 [PMID : 11794168]
 
6) Finfer S, et al : Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 360 : 1283-1297, 2009 [PMID : 19318384]
 
7) 米国集中治療医学会 (Society of Critical Care Medicine : SCCM) : Surviving Sepsis Campaign Guidelines 2021 https://www.sccm.org/Clinical-Resources/Guidelines/Guidelines/Surviving-Sepsis-Guidelines-2021
 
8) de Vries FE, et al : Meta-analysis of lower perioperative blood glucose target levels for reduction of surgical-site infection. Br J Surg, 104 : e95-e105, 2017 [PMID : 27901264]
 
9) Weimann A, et al : ESPEN Guidelines on Enteral Nutrition : Surgery including organ transplantation. Clin Nutr, 25 : 224-244, 2006 [PMID : 16698152]
 
10) Braga M, et al : ESPEN Guidelines on Parenteral Nutrition : surgery. Clin Nutr, 28 : 378-386, 2009 [PMID : 19464088]
 
P.165 掲載の参考文献
1) 栄養療法の種類と選択. 「静脈経腸栄養ガイドライン 第3版」 (日本静脈経腸栄養学会/編), pp13-23, 照林社 https://minds.jcqhc.or.jp/docs/minds/PEN/Parenteral_and_Enteral_Nutrition.pdf
 
2) 経腸栄養法. 「病態栄養専門医テキスト 改訂第3版」 (日本病態栄養学会/編), pp273-281, 南江堂, 2021
 
3) 経腸栄養のリスクマネジメント. 「静脈経腸栄養ガイドライン 第3版」 (日本静脈経腸栄養学会/編), pp113-119, 照林社
 
4) Finfer S, et al : Intensive versus conventional glucose control in critically ill patients. N Engl J Med, 360 : 1283-1297, 2009 [PMID : 19318384]
 
5) Gandhi GY, et al : Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery : a randomized trial. Ann Intern Med, 146 : 233-243, 2007 [PMID : 17310047]
 
6) 血糖管理. 「日本版重症患者の栄養療法ガイドライン」 (日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会/編), pp267-269, 2016 https://www.jstage.jst.go.jp/article/jsicm/23/2/23_185/_pdf
 
7) 特殊な病態における糖尿病治療. 「糖尿病専門医研修ガイドブック 改訂第8版」 (日本糖尿病学会/編), pp416-417, 診断と治療社, 2020
 
8) Hsia E, et al : Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy. Nutr Clin Pract, 26 : 714-717, 2011 [PMID : 22205560]
 
9) Pohl M, et al : Glycemic control in patients with type 2 diabetes mellitus with a disease-specific enteral formula : stage II of a randomized, controlled multicenter trial. JPEN J Parenter Enteral Nutr, 33 : 37-49, 2009 [PMID : 19011146]
 
10) Sanz-Paris A, et al : Diabetes-specific formulas high in monounsaturated fatty acids and metabolic outcomes in patients with diabetes or hyperglycaemia. A systematic review and meta-analysis. Clin Nutr, 39 : 3273-3282, 2020 [PMID : 32222291]
PubMed
P.175 掲載の参考文献
1) 厚生労働省 : 令和元年 国民健康・栄養調査報告. 2020 https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/eiyou/r1-houkoku_00002.html
 
2) Yamaguchi T, et al : A Survey of Bariatric/Metabolic Surgery as a Treatment Option for Patients with Severe Obesity and Type 2 Diabetes in Japan. Obes Surg, 32 : 926-929, 2022 [PMID : 34687409]
 
3) Miyazawa I, et al : Twelve-year trends of increasing overweight and obesity in patients with diabetes : the Shiga Diabetes Clinical Survey. Endocr J, 65 : 527-536, 2018 [PMID : 29526989]
 
4) 「肥満症診療ガイドライン 2016」 (日本肥満学会/編), ライフサイエンス出版, 2016
 
5) Fontaine KR, et al : Years of life lost due to obesity. JAMA, 289 : 187-193, 2003 [PMID : 12517229]
 
6) Jee SH, et al : Body-mass index and mortality in Korean men and women. N Engl J Med, 355 : 779-787, 2006 [PMID : 16926276]
 
7) Yokoyama H, et al : Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40). BMJ Open Diabetes Res Care, 4 : e000294, 2016 [PMID : 27752329]
 
8) 莇也寸志, 他 : 40歳以下2型糖尿病の多施設調査-登録時臨床像とライフスタイル・社会経済的状態の全国調査との比較-. 糖尿病, 59 : 95-104, 2016
 
9) 「糖尿病診療ガイドライン 2019」 (日本糖尿病学会/編著), 南江堂, 2019
 
10) 「日本人の肥満2型糖尿病患者に対する減量・代謝改善手術に関するコンセンサスステートメント」 (日本肥満症治療学会, 他/監, 日本人の肥満2型糖尿病患者に対する減量・代謝改善手術の適応基準に関する3学会合同委員会/編), コンパス出版局, 2021 http://plaza.umin.ne.jp/~jsto/publication/3gakkai-index.html
 
11) Bohdjalian A, et al : Sleeve gastrectomy as sole and definitive bariatric procedure : 5-year results for weight loss and ghrelin. Obes Surg, 20 : 535-540, 2010 [PMID : 20094819]
 
12) Peterli R, et al : Improvement in glucose metabolism after bariatric surgery : comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy : a prospective randomized trial. Ann Surg, 250 : 234-241, 2009 [PMID : 19638921]
 
13) Ryan KK, et al : FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature, 509 : 183-188, 2014 [PMID : 24670636]
 
14) 辻野元祥 : 減量外科手術から代謝改善手術へ～本邦における肥満外科治療ブレイクの背景にあるもの～. 日本職業・災害医学会会誌, 68 : 321-325, 2020
Medical*Online
15) Haruta H, et al : Long-Term Outcomes of Bariatric and Metabolic Surgery in Japan : Results of a Multi-Institutional Survey. Obes Surg, 27 : 754-762, 2017 [PMID : 27631329]
 
16) Seki Y, et al : Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for Type 2 Diabetes Mellitus. Obes Surg, 26 : 2035-2044, 2016 [PMID : 26749411]
 
17) Seki Y, et al : Five-Year-Results of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass for Weight Loss and Type 2 Diabetes Mellitus. Obes Surg, 27 : 795-801, 2017 [PMID : 27644433]
 
18) Rubino F, et al : Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes : A Joint Statement by International Diabetes Organizations. Diabetes Care, 39 : 861-877, 2016 [PMID : 27222544]
 
19) Cummings DE & Cohen RV : Bariatric/Metabolic Surgery to Treat Type 2 Diabetes in Patients With a BMI &lt ; 35 kg/m2. Diabetes Care, 39 : 924-933, 2016 [PMID : 27222550]
 
20) Sjostrom L, et al : Bariatric surgery and long-term cardiovascular events. JAMA, 307 : 56-65, 2012 [PMID : 22215166]
 
21) Aminian A, et al : Association of Metabolic Surgery With Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes and Obesity. JAMA, 322 : 1271-1282, 2019 [PMID : 31475297]
 
22) 遠藤裕一, 他 : 高度肥満症例に対する内視鏡的胃内バルーン留置術. 臨床雑誌外科, 81 : 211-214, 2019
 
23) Seki Y, et al : The Effects of Laparoscopic Sleeve Gastrectomy with Duodenojejunal Bypass on Japanese Patients with BMI< 35 kg/m2 on Type 2 Diabetes Mellitus and the Prediction of Successful Glycemic Control. Obes Surg, 28 : 2429-2438, 2018 [PMID : 29502278]
 
24) Seki Y, et al : Metabolic surgery for inadequately controlled type 2 diabetes in nonseverely obese Japanese : a prospective, single-center study. Surg Obes Relat Dis, 14 : 978-985, 2018 [PMID : 29724682]
 
25) Seki Y, et al : Impact of metabolic surgery on health-related quality of life and quality of alimentation. Surg Obes Relat Dis, 15 : 488-496, 2019 [PMID : 30711445]
 

第4章 困ったときへの対応

P.185 掲載の参考文献
1) Evert AB, et al : Nutrition Therapy for Adults With Diabetes or Prediabetes : A Consensus Report. Diabetes Care, 42 : 731-754, 2019 [PMID : 31000505]
 
2) Murdoch C, et al : Adapting diabetes medication for low carbohydrate management of type 2 diabetes : a practical guide. Br J Gen Pract, 69 : 360-361, 2019 [PMID : 31249097]
 
3) Griauzde DH, et al : A Pragmatic Approach to Translating Low- and Very Low-Carbohydrate Diets Into Clinical Practice for Patients With Obesity and Type 2 Diabetes. Front Nutr, 8 : 682137, 2021 [PMID : 34350205]
 
4) Lennerz BS, et al : Carbohydrate restriction for diabetes : rediscovering centuries-old wisdom. J Clin Invest, 131 : doi : 10.1172/JCI142246, 2021 [PMID : 33393511]
 
5) Shai I, et al : Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med, 359 : 229-241, 2008 [PMID : 18635428]
 
6) McArdle PD, et al : Carbohydrate restriction for glycaemic control in Type 2 diabetes : a systematic review and meta-analysis. Diabet Med, 36 : 335-348, 2019 [PMID : 30426553]
 
7) Goldenberg JZ, et al : Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission : systematic review and meta-analysis of published and unpublished randomized trial data. BMJ, 372 : m4743, 2021 [PMID : 33441384]
 
8) Yamada Y, et al : A non-calorie-restricted low-carbohydrate diet is effective as an alternative therapy for patients with type 2 diabetes. Intern Med, 53 : 13-19, 2014 [PMID : 24390522]
 
9) Ramsden CE, et al : Use of dietary linoleic acid for secondary prevention of coronary heart disease and death : evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ, 346 : e8707, 2013 [PMID : 23386268]
 
10) Astrup A, et al : Saturated Fats and Health : A Reassessment and Proposal for Food-Based Recommendations : JACC State-of-the-Art Review. J Am Coll Cardiol, 76 : 844-857, 2020 [PMID : 32562735]
 
P.191 掲載の参考文献
1) 宇佐見啓治 : 肥満を伴うNIDDM患者に対する筋力トレーニングの効果について. 第15回日本肥満学会記録, 103-105, 1994
 
2) 佐藤祐造, 他 : わが国における糖尿病運動療法の実施状況 (第2報) -患者側への質問紙全国調査成績-. 糖尿病, 58 : 850-859, 2015
 
3) 「糖尿病運動療法指導の手びき」 (佐藤祐造/編著), pp64-66, 南江堂, 1991
 
4) 石井伴房, 他 : 糖尿病患者におけるインスリン感受性に及ぼす筋力トレーニングの影響. 臨床スポーツ医学, 13 : 933-935, 1996
Medical*Online
5) 「最新 糖尿病の運動療法ガイド」 (米国糖尿病学会/著, 中尾一和/監訳), pp193-195, メジカルビュー社, 1997
 
6) DeFronzo RA : Lilly lecture 1987. The triumvirate : beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes, 37 : 667-687, 1988 [PMID : 3289989]
 
7) Abe T, et al : Effects of 20 days bed rest on muscle morphology. J Gravit Physiol, 4 : S10-S14, 1997 [PMID : 11541170]
 
8) Thorburn AW, et al : Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest, 87 : 489-495, 1991 [PMID : 1899428]
 
9) Paschalis V, et al : Equal volumes of high and low intensity of eccentric exercise in relation to muscle damage and performance. J Strength Cond Res, 19 : 184-188, 2005 [PMID : 15705032]
 
10) Chen TC, et al : Effects of Descending Stair Walking on Health and Fitness of Elderly Obese Women. Med Sci Sports Exerc, 49 : 1614-1622, 2017 [PMID : 28291022]
 
11) 宇佐見啓治 : かかりつけ医の役割 外来でできる運動指導. 治療, 90 : 3071-3075, 2008
 
P.196 掲載の参考文献
1) Joboshi H & Oka M : Effectiveness of an educational intervention (the Encourage Autonomous Self-Enrichment Program) in patients with chronic kidney disease : A randomized controlled trial. Int J Nurs Stud, 67 : 51-58, 2017 [PMID : 27918931]
 
2) 岡美智代, 他 : 慢性疾患患者さんの生きがいを共有しながら行う行動変容支援 : 「EASEプログラム」と「じっくりEASEプログラム」とは. 看護のチカラ, 27 : 32-40, 2022
 
3) McGovern A, et al : Comparison of medication adherence and persistence in type 2 diabetes : A systematic review and meta-analysis. Diabetes Obes Metab, 20 : 1040-1043, 2018 [PMID : 29135080]
 
4) Yu JH, et al : Factors influencing psychological insulin resistance in type 2 diabetes patients. Int J Nurs Pract, 25 : e12733, 2019 [PMID : 30945437]
 
P.202 掲載の参考文献
1) Asche C, et al : A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther, 33 : 74-109, 2011 [PMID : 21397776]
 
2) Flory J, et al : Comparative adherence to diabetes drugs : An analysis of electronic health records and claims data. Diabetes Obes Metab, 19 : 1184-1187, 2017 [PMID : 28266807]
 
3) Jha AK, et al : Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood), 31 : 1836-1846, 2012 [PMID : 22869663]
 
4) Kennedy-Martin T, et al : Cost of medication adherence and persistence in type 2 diabetes mellitus : a literature review. Patient Prefer Adherence, 11 : 1103-1117, 2017 [PMID : 28721024]
 
5) Iglay K, et al : Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. Curr Med Res Opin, 31 : 1283-1296, 2015 [PMID : 26023805]
 
6) Baser O, et al : Real-world outcomes of initiating insulin glargine-based treatment versus premixed analog insulins among US patients with type 2 diabetes failing oral antidiabetic drugs. Clinicoecon Outcomes Res, 5 : 497-505, 2013 [PMID : 24124384]
 
7) Aikens JE, et al : Longitudinal association between medication adherence and glycaemic control in Type 2 diabetes. Diabet Med, 30 : 338-344, 2013 [PMID : 23075262]
 
8) Hong JS, et al : Relationship between oral antihyperglycemic medication adherence and hospitalization, mortality, and healthcare costs in adult ambulatory care patients with type 2 diabetes in South Korea. Med Care, 49 : 378-384, 2011 [PMID : 21368684]
 
9) Abegunde DO, et al : The burden and costs of chronic diseases in low-income and middle-income countries. Lancet, 370 : 1929-1938, 2007 [PMID : 18063029]
 
10) World H ea lt h Orga nizat ion : Adherence to l ong -ter m t herapies : evidence for act ion. 2003 https://apps.who.int/iris/bitstream/handle/10665/42682/9241545992.pdf?sequence=1&isAllowed=y
 
11) Hall JA, et al : Meta-analysis of correlates of provider behavior in medical encounters. Med Care, 26 : 657-675, 1988 [PMID : 3292851]
 
12) Schulman BA : Active patient orientation and outcomes in hypertensive treatment : application of a socio-organizational perspective. Med Care, 17 : 267-280, 1979 [PMID : 763004]
 
13) Dunbar JM & Agras WS : Compliance with Medical Instructions.「The Comprehensive Handbook of Behavioral Medicine」 (Ferguson JM & Taylor CB, eds), pp115-145, Spectrum, 1980
 
14) Stewart MA : Effective physician-patient communication and health outcomes : a review. CMAJ, 152 : 1423-1433, 1995 [PMID : 7728691]
 
15) Ammerman AS, et al : Physician-based diet counseling for cholesterol reduction : current practices, determinants, and strategies for improvement. Prev Med, 22 : 96-109, 1993 [PMID : 8475015]
 
16) 「Facilitating treatment adherence : A practitioner's guidebook」 (Meichenbaum D & Turk DC, eds), Plenum Press, 1987
 
17) Turk D, et al : Adherence : A cognitive behavioural perspective.「Compliance : The dilemma of the chronically ill」 (Gerber K & Nehemkis A, eds), pp44-72, Springer, 1986
 
18) Lee DSU, et al : Adherence and persistence rates of major antidiabetic medications : a review. Diabetol Metab Syndr, 14 : 12, 2022 [PMID : 35033161]
 
19) Nishimura R, et al : Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan : a claims-based cohort study. BMJ Open, 9 : e025806, 2019 [PMID : 30826768]
 
20) Bell KF, et al : Comparing Medication Adherence and Persistence Among Patients with Type 2 Diabetes Using Sodium-Glucose Cotransporter 2 Inhibitors or Sulfonylureas. Am Health Drug Benefits, 10 : 165-174, 2017 [PMID : 28794821]
PubMed
21) Guerci B, et al : Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes Metab, 45 : 528-535, 2019 [PMID : 30677504]
 
22) Mody R, et al : Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise : 6-month follow-up from US real-world data. Diabetes Obes Metab, 23 : 106-115, 2021 [PMID : 32945083]
 
23) Tofe S, et al : An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. Endocr Metab Sci, 2 : 100082, 2021
 
24) Sikirica MV, et al : Reasons for discontinuation of GLP1 receptor agonists : data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes, 10 : 403-412, 2017 [PMID : 29033597]
 
25) Fisher JD, et al : Changing AIDS-risk behavior. Psychol Bull, 111 : 455-474, 1992 [PMID : 1594721]
 
26) DiMatteo MR & DiNicola DD : Achieving patient compliance.「Patient Education and Counseling」 (Shope JT, ed), p51, Pergamon Press, 1983
 
P.209 掲載の参考文献
1) 「糖尿病医療者のための災害時糖尿病診療マニュアル」 (日本糖尿病学会/編著), 文光堂, 2014
 
2) 八幡和明 : 新潟県中越地震の経験から災害時の糖尿病医療を考える. Diabetes Frontier, 23 : 126-130, 2012
Medical*Online
3) 八幡和明 : 糖尿患者さんのための災害マニュアル. 2014 https://www.jnj.co.jp/jjmkk/lifescan/disaster_manual.pdf
 
4) 安西慶三, 荒木栄一 : 糖尿病の災害時支援体制. DM Ensemble, 10 : 7-10, 2021
 
5) 日本糖尿病協会 : 糖尿病連携手帳挟み込み型 防災リーフレット https://www.nittokyo.or.jp/modules/patient/index.php?content_id=32
 
P.214 掲載の参考文献
1) American Diabetes Association Professional Practice Committee, et al : 9. Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 (Suppl 1) : S125-S143, 2022
 
2) 一般社団法人 日本糖尿病学会 : GLP-1受容体作動薬適応外使用に関する日本糖尿病学会の見解. 2020年7月9日 http://www.fa.kyorin.co.jp/jds/uploads/jds_statement_GLP-1.pdf
 
3) 朝日新聞阪神版, 2002年6月11日, p28
 
「続・これなら簡単今すぐできる外来インスリン導入」 (弘世貴久/著), メディカルレビュー社, 2009
 
「もう迷わない! 外来インスリン療法マスターブック」 (弘世貴久/著), 南江堂, 2013
 
P.221 掲載の参考文献
1) Gentile S, et al : Insulin-Induced Skin Lipohypertrophy in Type 2 Diabetes : a Multicenter Regional Survey in Southern Italy. Diabetes Ther, 11 : 2001-2017, 2020 [PMID : 32683659]
 
2) Thewjitcharoen Y, et al : Prevalence, Risk Factors, and Clinical Characteristics of Lipodystrophy in Insulin-Treated Patients with Diabetes : An Old Problem in a New Era of Modern Insulin. Diabetes Metab Syndr Obes, 13 : 4609-4620, 2020 [PMID : 33273836]
 
3) Nagase T, et al : The insulin ball. Lancet, 373 : 184, 2009 [PMID : 19135614]
 
4) Nagase T, et al : Insulin-derived amyloidosis and poor glycemic control : a case series. Am J Med, 127 : 450-454, 2014 [PMID : 24462809]
 
5) Nagase T, et al : Insulin-derived amyloidosis without a palpable mass at the insulin injection site : A report of two cases. J Diabetes Investig, 11 : 1002-1005, 2020 [PMID : 31867887]
 
6) Ansari AM, et al : Current insight in the localized insulin-derived amyloidosis (LIDA) : clinico-pathological characteristics and differential diagnosis. Pathol Res Pract, 213 : 1237-1241, 2017 [PMID : 28935176]
 
7) Nilsson MR : Insulin amyloid at injection sites of patients with diabetes. Amyloid, 23 : 139-147, 2016 [PMID : 27159045]
 
8) Famulla S, et al : Insulin Injection Into Lipohypertrophic Tissue : Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care, 39 : 1486-1492, 2016 [PMID : 27411698]
 
9) Kikuchi M, et al : Ultrasonography Improves Glycemic Control by Detecting Insulin-Derived Localized Amyloidosis. Ultrasound Med Biol, 43 : 2284-2294, 2017 [PMID : 28754497]
 
10) Frid AH, et al : New Insulin Delivery Recommendations. Mayo Clin Proc, 91 : 1231-1255, 2016 [PMID : 27594187]
 
P.229 掲載の参考文献
1) 朝倉俊成 : 適正な注射 手技. 「糖尿病の薬学管理必携糖尿病薬物療法認定剤師ガイドブック」 (清野裕, 他/監, 日本くすりと糖尿病学会/編), じほう, pp191-201, 2017
 
2) 「糖尿病治療マスターのための注射療法マニュアル」 (清野弘明, 朝倉俊成/編著), p216, 南江堂, 2020
 
3) 朝倉俊成 : ～日本糖尿病協会糖尿病医薬品・医療機器等適正化委員会の取り組みから～ インスリン製剤やGLP-1受容体作動薬を識別する方法. さかえ, 58 (7) : 36-43, 2018
 
4) 朝倉俊成 : 高温環境下でのインスリン製剤の保管に関する提案. くすりと糖尿病, 9 : 104-113, 2020
 
5) 日本くすりと糖尿病学会 : 高温環境下でのインスリン製剤の保管に関する提案. くすりと糖尿病, 10 (別冊) : 118-119, 2021
 
6) 日本くすりと糖尿病学会 : 糖尿病治療用注射製剤に関わる「補助具」の適正使用のための留意点. くすりと糖尿病, 10 (別冊) : 115-117, 2021
 

第5章 地域連携

P.239 掲載の参考文献
1) 厚生労働省 : 糖尿病性腎症重症化予防プログラム (概要) https://www.mhlw.go.jp/content/12401000/gaiyou.pdf
 
2) 「糖尿病治療ガイド 2022-2023」 (日本糖尿病学会/編著), 文光堂, 2022
 
3) Hamasaki H, et al : Association of handgrip strength with hospitalization, cardiovascular events, and mortality in Japanese patients with type 2 diabetes. Sci Rep, 7 : 7041, 2017 [PMID : 28765572]
 
4) 西岡恵子, 他 : 糖尿病連携手帳の地域連携への活用. DM Ensemble, 9 : 12-19, 2020
 
5) 矢部大介, 他 : 糖尿病性腎症重症化予防プログラムと糖尿病連携手帳の活用. DM Ensemble, 9 : 20-25, 2020
 
P.246 掲載の参考文献
1) 厚生労働省 : 令和元年 国民健康・栄養調査結果の概要. 2019 https://www.mhlw.go.jp/content/10900000/000687163.pdf
 
2) 日本専門医機構 : 各学会の会員数及び専門医数等の一覧表. 日本専門医制度概報, 令和2年 (2020年) 度版, 2021 https://jmsb.or.jp/wp-content/uploads/2021/03/gaiho_2020.pdf (2022年9月閲覧)
 
P.252 掲載の参考文献
1) 厚生労働省 : 患者のための薬局ビジョン～「門前」から「かかりつけ」, そして「地域」へ～. 2015 https://www.mhlw.go.jp/file/04-Houdouhappyou-11121000-Iyakushokuhinkyoku-Soumuka/vision_1.pdf
 
2) 日本薬剤師会 : 薬剤使用期間中の患者フォローアップの手引き (第1.2版). 2022 https://www.nichiyaku.or.jp/assets/uploads/pharmacy-info/followup_1.2.pdf
 
3) Presley B, et al : Pharmacy-led interventions to improve medication adherence among adults with diabetes : A systematic review and meta-analysis. Res Social Adm Pharm, 15 : 1057-1067, 2019 [PMID : 30685443]
 
4) 船越順子, 他 : 電話による退院患者のフォローアップ. 医療薬学, 27 : 548-552, 2001
Medical*Online
5) 吉留実慧子, 他 : 保険薬局による電話連絡とトレーシングレポートを利用した経口抗がん剤服用外来患者に対する情報提供方法の確立. 医療薬学, 42 : 476-482, 2016
Medical*Online
6) 加藤良隆, 他 : 薬剤師外来とテレフォンフォローアップを利用し病院薬剤師と保険薬局薬剤師が連携・介入した一例-外来がん化学療法施行患者への介入を通して-. 医療薬学, 46 : 22-30, 2020
Medical*Online
7) 鎌田悠 : LINEを用いた服薬期間中のフォロー. 調剤と情報, 26 : 36-39, 2020
 
8) 日本保険薬局協会医療制度検討委員会 : 服用期間中フォローアップ事例と成果の収集. 2020 https://secure.nippon-pa.org/mail/img/npha20200911.pdf
 
9) 堀由美子, 他 : 保険薬局・ドラッグストアに勤務する管理栄養士・栄養士の配置状況と就業の実態. 栄養学雑誌, 79 : 242-252, 2021
Medical*Online
10) Iwasaki M, et al : Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes : Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels. J Diabetes Investig, 3 : 464-467, 2012 [PMID : 24843607]
 
11) Yasukata, F : A study regarding the development of a tool for developing self-efficacy in regard to dietary self-management for diabetes patients. Doctoral dissertation. Graduate School of Medicine, University of Tokyo, 1997
 
12) Shoji M, et al : A pilot study of Pharmacist-Dietician Collaborative support and Advice (PDCA) for patients with type 2 diabetes in community pharmacy : A single-arm, pre-post study. Pharm Pract, 20 : 2657, 2022
PubMed

第6章 先進医療の活用

P.258 掲載の参考文献
1) Imrisek SD, et al : Effects of a Novel Blood Glucose Forecasting Feature on Glycemic Management and Logging in Adults With Type 2 Diabetes Using One Drop : Retrospective Cohort Study. JMIR Diabetes, 7 : e34624, 2022 [PMID : 35503521]
 
2) Polonsky WH, et al : Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes : results from the Structured Testing Program study. Diabetes Care, 34 : 262-267, 2011 [PMID : 21270183]
 
3) Cutruzzola A, et al : Time spent in target range assessed by self-monitoring blood glucose associates with glycated hemoglobin in insulin treated patients with diabetes. Nutr Metab Cardiovasc Dis, 30 : 1800-1805, 2020 [PMID : 32669240]
 
4) Lunze K, et al : Blood glucose control algorithms for type 1 diabetic patients : A methodological review. Biomedical Signal Processing and Control, 8 : 107-119, 2013
 
5) Abrahamson MJ & Peters A : Intensification of insulin therapy in patients with type 2 diabetes mellitus : an algorithm for basal-bolus therapy. Ann Med, 44 : 836-846, 2012 [PMID : 22822902]
 
6) Rosenstock J, et al : Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med, 383 : 2107-2116, 2020 [PMID : 32960514]
 
7) Perreault L, et al : Initiation and Titration of Basal Insulin in Primary Care : Barriers and Practical Solutions. J Am Board Fam Med, 32 : 431-447, 2019 [PMID : 31068410]
 
P.263 掲載の参考文献
1) 渥美義仁 : 血糖変動への挑戦 : 把握・解析・統合・指導. 「いま読んでおきたい! 血糖データの活かし方」 (小出景子, 渥美義仁/編), pp2-8, 南山堂, 2020
 
2) 森豊 : CGM/FGMプロを用いた経口剤の薬効評価. 「いま読んでおきたい! 血糖データの活かし方」 (小出景子, 渥美義仁/編), pp120-129, 南山堂, 2020
 
3) 小出景子 : CGMの進歩と応用. 医学のあゆみ, 276 : 334-338, 2021
Medical*Online
4) Battelino T, et al : Clinical Targets for Continuous Glucose Monitoring Data Interpretation : Recommendations From the International Consensus on Time in Range. Diabetes Care, 42 : 1593-1603, 2019 [PMID : 31177185]
 
5) Bergenstal RM, et al : Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes : the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther, 15 : 198-211, 2013 [PMID : 23448694]
 
6) 小出景子 : 医療スタッフが行うDMS指導. 「いま読んでおきたい! 血糖データの活かし方」 (小出景子, 渥美義仁/編), pp9-18, 南山堂, 2020
 
P.272 掲載の参考文献
1) Bergenstal RM, et al : Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med, 369 : 224-232, 2013 [PMID : 23789889]
 
2) Yeh HC, et al : Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus : a systematic review and meta-analysis. Ann Intern Med, 157 : 336-347, 2012 [PMID : 22777524]
 
3) Pickup J, et al : Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes : meta-analysis of randomised controlled trials. BMJ, 324 : 705, 2002 [PMID : 11909787]
 
4) Karges B, et al : Association of Insulin Pump Therapy vs Insulin Injection Therapy With Severe Hypoglycemia, Ketoacidosis, and Glycemic Control Among Children, Adolescents, and Young Adults With Type 1 Diabetes. JAMA, 318 : 1358-1366, 2017 [PMID : 29049584]
 
5) Haynes A, et al : Severe hypoglycemia rates are not associated with HbA1c : a cross-sectional analysis of 3 contemporary pediatric diabetes registry databases. Pediatr Diabetes, 18 : 643-650, 2017 [PMID : 27878914]
 
6) Zabeen B, et al : Insulin Pump Therapy Is Associated with Lower Rates of Retinopathy and Peripheral Nerve Abnormality. PLoS One, 11 : e0153033, 2016 [PMID : 27050468]
 
7) Weintrob N, et al : Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes : a randomized open crossover trial. Pediatrics, 112 : 559-564, 2003 [PMID : 12949284]
 
8) Opipari-Arrigan L, et al : Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus. Pediatr Diabetes, 8 : 377-383, 2007 [PMID : 18036064]
 
9) 小林哲郎, 他 : 日本先進糖尿病治療研究会によるCSIIおよびCGMに関するステートメント. 糖尿病, 57 : 403-415, 2014
 
10) American Diabetes Association : Standards of Medical Care in Diabetes-2022. Diabetes Care, 45 : S104, 2022
 
P.279 掲載の参考文献
1) Xiao D, et al : The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients. Int J Endocrinol, 2016 : 4350712, 2016 [PMID : 26977146]
 
2) Hou W, et al : Polymorphism of organic cation transporter 2 improves glucose-lowering effect of metformin via influencing its pharmacokinetics in Chinese type 2 diabetic patients. Mol Diagn Ther, 19 : 25-33, 2015 [PMID : 25573751]
 
3) He R, et al : SLC47A1 gene rs2289669 G&gt ; A variants enhance the glucose-lowering effect of metformin via delaying its excretion in Chinese type 2 diabetes patients. Diabetes Res Clin Pract, 109 : 57-63, 2015 [PMID : 26004431]
 
4) Phani NM, et al : Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes. Pharmacogenomics, 19 : 905-911, 2018 [PMID : 29914345]
 
5) Dawed AY, et al : Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes : An IMI DIRECT Study. Diabetes Care, 42 : 1027-1033, 2019 [PMID : 30885951]
 
6) Feng Y, et al : Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care, 31 : 1939-1944, 2008 [PMID : 18599530]
 
7) Li Q, et al : KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol, 41 : 748-754, 2014 [PMID : 25115353]
 
8) Castelan-Martinez OD, et al : CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide. J Clin Pharm Ther, 43 : 768-774, 2018 [PMID : 29802808]
 
9) Li Q, et al : Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes. Acta Pharmacol Sin, 38 : 80-89, 2017 [PMID : 27694910]
 
10) Zhou X, et al : A Variation in the ABCC8 Gene Is Associated with Type 2 Diabetes Mellitus and Repaglinide Efficacy in Chinese Type 2 Diabetes Mellitus Patients. Intern Med, 58 : 2341-2347, 2019 [PMID : 31118371]
 
11) Yu M, et al : KCNJ11 Lys23Glu and TCF7L2 rs290487 (C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther, 87 : 330-335, 2010 [PMID : 20054294]
 
12) Kalliokoski A, et al : The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol, 66 : 818-825, 2008 [PMID : 18823304]
 
13) Dai XP, et al : KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol, 39 : 462-468, 2012 [PMID : 22414228]
 
14) Hsieh MC, et al : Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism, 59 : 1139-1144, 2010 [PMID : 20045142]
 
15) Andrulionyte L, et al : Single nucleotide polymorphisms of the peroxisome proliferator-activated receptor-alpha gene (PPARA) influence the conversion from impaired glucose tolerance to type 2 diabetes : the STOP-NIDDM trial. Diabetes, 56 : 1181-1186, 2007 [PMID : 17317762]
 
16) Han E, et al : A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes. Medicine (Baltimore), 95 : e5155, 2016 [PMID : 27858848]
 
17) Francke S, et al : In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol, 55 : 1061-1072, 2015 [PMID : 25827774]
 

書評

最近チェックした商品履歴

Loading...